Stay updated with breaking news from Transcode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the shares of the stock are short sold. Based on […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the company’s stock are sold short. Based […]